Business
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old
Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Techn
About this update from Dbv Technologies Sa
[{"type":"image","alt":"DBV Technologies S.A.","displaySize":"","headline":null,"caption":"DBV Technologies S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":157,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/06466da7ac8627e27b0291db4f69adde"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nRDNubmRBJgeAgXMmddvoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/06466da7ac8627e27b0291db4f69adde","width":157,"height":157}},"lazy":false},{"type":"text","content":"Châtillon, France, June 25, 2025","length":32,"tagName":"p"},{"type":"text","content":"DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old","length":139,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal Investigator","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"Additional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings","length":178,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":317,"olType":false},{"type":"text","content":"DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company’s COMFORT Toddlers supplemental safety study using the Viaskin® Peanut patch 250 μg in peanut-allergic children ages 1 – 3 years old.","length":310,"tagName":"p"},{"type":"text","content":"COMFORT Toddlers will enroll approximately 480 subjects at approximately 80 – 90 study centers across the U.S., Canada, Australia, UK and Europe. Principal Investigator, Jeffrey Leflein, MD, FAAAAI, FACAAI from the Respiratory Medicine Research Institute of Michigan, in Ann Arbor, Michigan screened the first subject in the study. Additionally, Dr. Doug McMahon, MD, Allergy and Asthma Center in Maplewood, Minnesota and Dr. Jason Ohayon, MD, Hamilton Allergy and Immunology Clinic in Ontario, Canada have been activated and are currently open to recruitment.","length":560,"tagName":"p"},{"type":"text","content":""I am thrilled that our talen...